Results 21 to 30 of about 1,205,134 (266)

Analyse von Orphan-Drug-Verfahren in der frühen Nutzenbewertung: RCTs versus best-verfügbare vergleichende Evidenz

open access: yesMonitor Versorgungsforschung, 2023
Zur Beurteilung der Wirksamkeit und Sicherheit eines neuen Wirkstoffes ist für die europäische Zulassungsbehörde (European Medicines Agency, EMA) die randomisierte kontrollierte Studie (RCT) der Goldstandard.
Dr. rer. nat. Gerrit Müller   +2 more
doaj   +1 more source

Targeting mitochondrial quality control in muscle aging: Natural dietary products as potential interventions

open access: yesFood Frontiers, 2023
Mitochondria are the main sources of energy production for muscle tissues, including skeletal, cardiac, or smooth muscle, to support their activities.
Qi Chen   +4 more
doaj   +1 more source

A machine learning approach for identifying variables associated with risk of developing neutralizing antidrug antibodies to factor VIII

open access: yesHeliyon, 2023
A key unmet need in the management of hemophilia A (HA) is the lack of clinically validated markers that are associated with the development of neutralizing antibodies to Factor VIII (FVIII) (commonly referred to as inhibitors).
Atul Rawal   +5 more
doaj   +1 more source

A proposed methodology for prioritizing project effects to include in cost-benefit analysis using resilience, vulnerability and risk perception [PDF]

open access: yes, 2014
Cost-benefit analysis (CBA) has emerged as one of the most widely used methodologies in environmental policy analysis, with many governments applying it in their decision-making procedures and laws.
Hanley, Nick   +8 more
core   +1 more source

Considering Local Air Pollution in the Benefit Assessment and Cost Allocation of Cross Border Transmission Projects

open access: yesEnergies, 2020
Developing a regional power system to achieve a high level of integration of national systems requires sufficient development of the regional transmission grid.
Deniz Sun, Luis Olmos, Michel Rivier
doaj   +1 more source

Low concentrations of perfluoroalkyl acids (PFAAs) in municipal drinking water associated with serum PFAA concentrations in Swedish adolescents

open access: yesEnvironment International, 2023
While highly contaminated drinking water (DW) is a major source of exposure to perfluoroalkyl acids (PFAAs), the contribution of low-level contaminated DW (i.e. 
Jennifer Nyström-Kandola   +7 more
doaj   +1 more source

Estimation of intake and quantification of hemoglobin adducts of acrylamide in adolescents in Sweden

open access: yesFrontiers in Nutrition
Blood samples (n = 600) from participants in the Swedish dietary survey Riksmaten Adolescents 2016–17 were analyzed with respect to hemoglobin (Hb) adducts from acrylamide (AA) and its metabolite glycidamide (GA) as biomarkers of internal dose/exposure ...
Efstathios Vryonidis   +4 more
doaj   +1 more source

Surrogatvalidierung durch Korrelation und Surrogate Threshold Effect – Ergebnisse von Simulationsstudien

open access: yesGMS Medizinische Informatik, Biometrie und Epidemiologie, 2017
Background: Progression-free survival (PFS) is often used instead of the patient-relevant endpoint overall survival (OS) in cancer clinical trials.
Gillhaus, Johanna   +3 more
doaj   +1 more source

Per- and polyfluoroalkyl substances (PFAS) and fetal growth: A nation-wide register-based study on PFAS in drinking water

open access: yesEnvironment International
Background: There is inconclusive evidence for an association between per- and polyfluoroalkyl substances (PFAS) and fetal growth. Objectives: We conducted a nation-wide register-based cohort study to assess the associations of the estimated maternal ...
Melle Säve-Söderbergh   +10 more
doaj   +1 more source

Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies

open access: yesJournal of the Medical Library Association, 2021
Introduction: Poor indexing and inconsistent use of terms and keywords may prevent efficient retrieval of studies on the patient-based benefit-risk assessment (BRA) of medicines.
Hiba El Masri   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy